CClinicalTrials.gg
CompletedNCT00645203Updated Mar 27, 2008

Safety and Efficacy Study of Cefdinir Oral Suspension, in Pediatric Subjects to Treat Acute Otitis Media

A Phase 2/3 interventional study of cefdinir in Acute Otitis Media, sponsored by Abbott. Completed at 22 sites in 7 countries. Open to participants aged 6 Months to 4 Years. Per ClinicalTrials.gov, last updated 2008-03-27.

Sponsored by Abbott · Phase 2/3, Interventional, and Treatment

Phase
Phase 2/3
Study type
Interventional
Enrollment
447
Allocation
Non-randomized
Ages
6 Months to 4 Years
Sex
All
01

Study summary

To evaluate the safety and efficacy of cefdinir oral suspension in children between 6 months and 4 years of age, with acute otitis media, who are at risk of persistent or recurrent otitis media.

02

Conditions studied

  • Acute Otitis Media
03

In context

Otitis

246 studies on the registry are indexed under Otitis; 21 are open to participants now.

This study's enrollment of 447 is above the median of 126 across 173 interventional studies indexed under Otitis.

Browse Otitis studies →

Lead sponsor

Abbott is the lead sponsor of 350 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 4 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male and female children between 6 months and 4 years of age
  • Weight does not exceed 40 kg
  • Clinical diagnosis is acute otitis media
  • Have evidence of middle ear fluid
  • At risk for persistent or recurrent otitis media
  • Generally in good health

Exclusion criteria

Exclusion Criteria:

  • Sensitivity or allergy to penicillins or cephalosporins or inability to take oral medications
  • Presence of tympanostomy tubes, ventilation tube or perforated tympanic membrane, in either ear
  • Treatment with any anti-infective agent within 3 days prior to the study or treatment with a long-acting injectable antimicrobial agent (e.g. , penicillin G benzathine) within 4 weeks prior to the study
  • Concomitant infection, that requires additional antimicrobial therapy
  • Presence of a disease, complicating factor (e.g., mastoiditis), or structural abnormality that would preclude evaluation of the patient's therapeutic response
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
447 participants (actual)

Study arms

  • Other
    1

    Drug: cefdinir

Interventions

  • Drugcefdinir

    cefdinir oral suspension, 25 mg/kg once daily for 10 days

    Also known as: ABT-198, Omnicef, cefdinir

06

What researchers measure

Primary outcomes

  1. Bacteriological Response

    Time frame: 30 days

  2. Clinical response

    Time frame: 30 days

  3. Change in the otoscopic findings

    Time frame: 30 days

Secondary outcomes

  1. Physical exam; Vital signs; Use of concomitant medications

    Time frame: 59 days

  2. Adverse events assessment

    Time frame: 45 days with follow-up to a satisfactory conclusion

  3. Laboratory evaluations

    Time frame: 30 days

07

Study locations

22 sites
  • Scottsdale, Arizona 85258, United States
  • Clovis, California 93611, United States
  • Dinuba, California 93618, United States
  • Folsom, California 95630, United States
  • Denver, Colorado 80218, United States
  • Brooklyn, New York 11203, United States
  • Rochester, New York 14618, United States
  • Rochester, New York 14620, United States
  • Chapel Hill, North Carolina 27514, United States
  • Erie, Pennsylvania 16508, United States
  • Pittsburgh, Pennsylvania 15213, United States
  • Dallas, Texas 75390-9035, United States
  • Salt Lake City, Utah 84113, United States
  • Providencia, Santiago, Chile
  • Puente Alto, Santiago, Chile
  • La Uruca, San Jose, Costa Rica
  • San Jose, Costa Rica
  • Santo Domingo, ZC 02, Dominican Republic
  • Guatemala City, 01011, Guatemala
  • Guatemala City, Guatemala
  • Beer Sheva, 84101, Israel
  • Panama, 4087, Panama
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 27, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00645203
Lead sponsor
Abbott
First posted
Mar 27, 2008
Start date
Jul 2002
Primary completion
Apr 2003
Last update
Mar 27, 2008
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion